Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Condition: Multiple Myeloma
MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell
Intervention: Bendamustine; Bortezomib; Dexamethasone
Intervention description: Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.; 1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15; 20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
Intervention MeSH terms: Dexamethasone; Bortezomib; Bendamustine Hydrochloride
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 59.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Multiple Myeloma; Bendamustine; Bortezomib; Dexamethasone

Summary:

      In this study, investigators will evaluate the activity of bendamustine, bortezomib and
      dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma,
      with different mechanisms of action and non-overlapping toxicities.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Patients must meet the Durie and Salmon criteria for initial diagnosis of multiple
             myeloma.

          2. Previously histologically confirmed, multiple myeloma with indication for therapy
             including one of the following:

               -  Hemoglobin <10 g/dl or 2 g/dl below normal

               -  Serum calcium >11.5 mg/dl

               -  Creatinine >2 mg/dl

               -  Lytic bone lesions or severe osteopenia

               -  Extramedullary plasmacytomas

          3. Patients should not be considered candidates for high dose therapy/autologous stem
             cell transplantation due to coexistent medical conditions, advanced age, poor
             performance status, refusal of high dose chemotherapy, or other reasons as judged by
             the patient and/or physician.

          4. ECOG Performance Status 0-2.

          5. WBC ≥3000/mL; ANC ≥1000/mL; platelets ≥50,000/mL (patients with platelets ≥30,000/mL
             are eligible if thrombocytopenia is felt to be due to extensive bone marrow
             involvement with myeloma).

          6. Patients with adequate organ function as measured by:

             Renal: Serum creatinine <2.0 mg/dL or a calculated or measured creatinine clearance of
             >30 mL/minute.

             Hepatic: Total bilirubin < 1.5 x ULN and ALT and AST <2.5 x the ULN (<5 x ULN for
             patients with liver involvement).

          7. Patients must have measurable or evaluable disease. In patients with disease limited
             to bone and bone marrow, serial paraprotein measurements are acceptable for evaluable
             disease.

          8. Patients must be accessible for treatment and follow-up procedures.

          9. Male or female patients 18 years of age or older.

         10. Patients must provide written informed consent prior to receiving protocol therapy.

         11. Women of childbearing potential must agree to use a medically acceptable method of
             birth control(e.g., a hormonal contraceptive, intra-uterine device, diaphragm with
             spermicide, condom with spermicide, or abstinence) for the duration of the study and
             for 12 months after their last dose of rituximab. Men must use an acceptable
             form/method of contraception for the duration of treatment and for 3 months after the
             end of treatment.

         12. Patients must be able to understand the nature of this study and give written informed
             consent.

        Exclusion Criteria:

          1. Previous therapy for multiple myeloma with the exception of an initial 4-day course of
             pulsed dexamethasone.

          2. Patients with ≥NCI CTCAE v4.0 grade 2 peripheral neuropathy ≤14 days prior to study
             enrollment.

          3. Treatment with investigational agent(s) ≤14 days prior to study enrollment.

          4. Active infection or infection requiring intravenous antibiotic treatment at the time
             of accrual.

          5. Known to be HIV positive (HIV test is not required for participation in the trial).

          6. Patients with class III/IV cardiac problems as defined by the New York Heart
             Association (NYHA)criteria:

               -  History of uncontrolled or symptomatic angina

               -  History of arrhythmias requiring medications, or clinically significant, with the
                  exception of asymptomatic atrial fibrillation requiring anticoagulation

               -  Myocardial infarction < 6 months from study entry

               -  Uncontrolled or symptomatic congestive heart failure

               -  Ejection fraction below the institutional normal limit

               -  Any other cardiac condition that, in the opinion of the treatment physician,
                  would make this protocol unreasonably hazardous for the patient

               -  Uncontrolled hypertension (systolic blood pressure [BP] >180 or diastolic BP
                  >100mm Hg)or uncontrolled cardiac arrhythmias.

               -  Prior to study entry, any ECG abnormality at Screening must be documented by the
                  investigator as not medically relevant.

          7. Other serious medical conditions or psychiatric illness that would potentially
             interfere with patient participation in this trial.

          8. A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma
             of the cervix,unless the tumor was treated with curative intent at least 2 years
             previously or low-risk prostate cancer after curative therapy.

          9. Known hypersensitivity to bortezomib, boron, or mannitol.

         10. Female patient is pregnant or lactating. Confirmation that female patients of
             childbearing potential are not pregnant must be established by a negative serum
             pregnancy test ≤7 days prior to start of treatment.